NL-OMON26268Not yet recruitingNot Applicable
Tumour-specific fluorescence-guided surgery for gastroenteropancreatic neuroendocrine neoplasms using PHT001: a phase 1, open-label, single-arm, dose-escalation study
Amsterdam UMC0 sites15 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 15
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Patients undergoing surgery for a primary GEP-NEN (stomach, duodenum, ampulla of Vater, pancreas, jejunum, ileum, colon or rectum), of any stage, grade and intent (i.e. curative/palliative) or metastases of a GEP-NEN;
- •SSTR-2 positive disease, as proven by a DOTATATE PET scan pre-operatively (conducted at location AMC and part of standard care);
- •Age of 18 years and older;
- •Written informed consent.
Exclusion Criteria
- •NEN, not meeting the inclusion criteria (non-GEP-NEN, unknown location);
- •Pregnant or breast-feeding women;
- •Known hypersensitivity to the investigational medicinal product (IMP) or any of its components;
- •Patients with an allergic/infusion reaction to 1 mg of TOC test dose of the unlabelled TOC;
- •Patients with known allergies to intravenous radiographic contrast agents;
- •Patients who have not provided a signed informed consent form to participate in the study, prior to the start of any protocol related activities;
- •Patients who, within the last 30 days, have participated in any clinical study of a therapeutic agent which may interfere with the safety or efficacy analysis of the IMP;
- •Serious non-malignant disease (e.g. psychiatric infectious, autoimmune, metabolic, renal, hepatic, cardiovascular or hematological), that may interfere with the objectives of the study or with the safety of the subject, as judged by the investigator;
- •A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms);
- •A history of additional risk factors for torsade de pointes (e.g., heart failure, hypokalaemia, family history of Long QT Syndrome);
- •The use of concomitant medications that prolong the QT/QTc interval.
Investigators
Similar Trials
Not yet recruiting
Phase 2
se of fluorescein in brain tumor surgeryCTRI/2019/01/017325Department of Neurosurgery
Recruiting
Phase 4
Fluorescence-guided (Minimally Invasive) resections of Colorectal liver metastases - II (MIMIC-II)colorectal liver metastasesmetastases in the liver from primary colon cancer1001981510019818NL-OMON56540eids Universitair Medisch Centrum52
Recruiting
Not Applicable
Fluorescence guided surgery for intra-operative detection of meningioma using Bevacizumab-IRDye800CWmeningiomaNL-OMON50918niversitair Medisch Centrum Groningen19
Active, not recruiting
Phase 1
Fluorescence imaging of meningioma tissue during an operatioMedDRA version: 21.1Level: PTClassification code 10027191Term: MeningiomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)meningiomaEUCTR2020-006141-19-NLniversity Medical Center Groningen19
Recruiting
Not Applicable
Fluorescence guided surgery for intra-operative detection of meningioma using Bevacizumab-IRDye800CWNL-OMON25431Department of Neurosurgery, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen19
